

A1

CONT.

4. (Amended) Composition according to Claim 3, [characterized in that]
wherein said polypeptide having cytotoxic activity is a cytokine [chosen] selected from the
group consisting of interferons α , β and γ , interleukins, tumor necrosis factors and colony
stimulating factors.

Claim 5, lines 1-2, change "characterized in that" to --wherein--.

Claim 6, lines 1-2, change "characterized in that" to --wherein--.

Claim 7, line 1, change "one of Claims 1 to 6" to --Claim 1--;
line 2, change "characterized in that it comprises" to --comprising--.

Claim 8, lines 1-2, change "characterized in that" to --wherein--;
line 3, after "from" insert --the group consisting of--.

Claim 9, lines 1-2, change "characterized in that" to --wherein--.

A2
10. (Amended) Composition according to Claim 4, [characterized in that]

wherein said polypeptide having cytotoxic activity is an anti-angiogenic protein factor
[chosen] selected from the group consisting of angiostatin, endostatin, platelet factor PF4,
thrombospondin-1, PRP, VEGI, metalloproteases and urokinase.

Claim 11, lines 1-2, change "characterized in that" to --wherein--.

Claim 12, line 2, change "characterized in that" to --wherein--.

Claim 13, line 2, change "characterized in that" to --wherein--.

Claim 15, lines 1-2, change "characterized in that it" to --wherein said vector--.

17. (Amended) Method for preparing a viral particle according to Claim 16,

[according to which] wherein:

- (i) introducing a viral vector according to claim 15 [is introduced] into a cell capable of producing said vector, so as to obtain a transfected cell,
- (ii) culturing said transfected cell [is cultured] under suitable conditions in order to allow the production of said viral particle, and
- (iii) recovering said viral particle [is recovered] from the cell culture.

Claim 18, line 7, change "Claims 1 to 10" to --Claim 1--.

Claim 19, lines 2-3. change "characterized in that it comprises" to --comprising--;

line 3, delete "one of Claims 1";

lines 4-5, delete in their entirety;

line 6, delete "according to according to" and change "18" to --1--;
line 7, change "acceptable from a pharmaceutical point of view" to
--pharmaceutically acceptable--.

Claim 20, lines 2-3, delete in their entirety;

line 4, delete "prodrug" and insert therefor --comprising--.

Claim 21, line 2, change "characterized in that" to --wherein-- and delete
"selected from";

line 3, change "and" to --or--.

Kindly cancel claim 22 without prejudice or disclaimer.

Kindly add the following claims:

A4
-23. The composition according to Claim 2, wherein said MIP1 chemokine is
MIP1 α or MIP1 β .

Sub B5
24. A method for treating a patient in need of a cytotoxic agent, said method
comprising administering an effective amount of the composition of Claim 1 to a patient in
need of such treatment.--

REMARKS

Entry of the foregoing amendments are respectfully requested.